XOMA Corp is a pharmaceutical company based in the United States that acts as a biotechnology royalty aggregator. They specialize in acquiring future economic rights related to pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. With an ESG score of 26.6, XOMA Corp is classified as a medium-risk company. Their unique business model helps biotech companies improve human health by providing non-dilutive and non-recourse funding for the advancement of drug candidates.